Joonghun Pharmaceutical Has Launched Artgaon to Compete With Top European Fillers
Joonghun Pharmaceutical has officially launched their premium cross-linked hyaluronic acid dermal filler, Artgaon.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005456/en/
Joonghun Pharmaceutical has officially launched their premium cross-linked hyaluronic acid dermal filler, Artgaon (Photo: Business Wire)
Artgaon, with its certification of the CE mark, is specifically aimed to target the European aesthetic market as its slogan states “The Finest, for European Professionals”. Joonghun Pharmaceutical is a pharmaceutical company in South Korea that specializes in Hyaluronic Acid Injections used in orthopedic treatments for 15 years. With their in-depth knowledge of HA characteristics, they were able to develop a dermal filler designed to compete against the top European brands in the aesthetics industry.
According to Dr. YeoHye Yoon, the Quality Director from Joonghun, the main vision for Artgaon during its product development was to provide a new aesthetic experience like no other for both the patient and practitioner. To deliver this experience, Artgaon was focused on two things: high quality and unique cross-linking technology.
Artgaon is manufactured under strict pharmaceutical guidelines despite dermal fillers being classified as medical devices. “This commitment enables us to have higher standards of safety for every component of the filler. For example, Artgaon is manufactured in cleanrooms that control particles as small as 10-micrometers. Naturally, this makes Artgaon extremely clean, which we believe would add to the confidence of doctors using our product.”
Artgaon’s unique cross-linking technology allows doctors to enjoy an injection force of a mere 7-8 newtons that is smooth and consistent. Despite this, Artgaon boasts high elastic (G prime) and cohesive properties when inside the skin. Joonghun claims that their formula for Artgaon shows natural results not only by looks but by experiences felt by patients as well. “Artgaon really allows the doctor to mold the beauty they want for their patients due to the low injection force coupled with high molding capabilities.”
The gel characteristics of Artgaon is to be expressed in their soon to be updated package designs. “Artgaon’s new package designs are based on the architectural structure of the industrial era, which remain firm and capture beauty even to this day. We wanted this architectural beauty from the industrial era to represent Artgaon’s gel structure; to be firm and attain its beauty even over time.”
The quality and performance of Artgaon has already surprised doctors who have tested Artgaon. It is only a matter of time until Artgaon disrupts the beauty market of Europe and the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005456/en/
Contact information
Tulay Genc | info@b2press.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 15:00:00 EET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom